$33.5M
The funding will support clinical development and drug discovery programmes derived from academic research.
AT
Apollo Therapeutics
Apollo Therapeutics develops innovative medicines based on academic medical research breakthroughs.
Cambridge, UK
$33.5MTotal raised
A Cambridge-headquartered biopharmaceutical company focused on translating fundamental medical research into innovative medicines through a hub-and-spoke portfolio model.
Team
RM
Richard Mason
CEO
Richard serves as chief executive officer at Apollo Therapeutics. He previously led Johnson & Johnson Innovation, EMEA and served on the UK vaccines task force.
LinkedIn